Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2020 Dec;25(12):e1930-e1955.
doi: 10.1002/onco.13548. Epub 2020 Nov 7.

Homeopathic Treatment as an Add-On Therapy May Improve Quality of Life and Prolong Survival in Patients with Non-Small Cell Lung Cancer: A Prospective, Randomized, Placebo-Controlled, Double-Blind, Three-Arm, Multicenter Study

Michael Frass  1   2 , Peter Lechleitner  3 , Christa Gründling  4 , Claudia Pirker  5 , Erwin Grasmuk-Siegl  5 , Julian Domayer  5 , Maximilian Hochmair  5 , Katharina Gaertner  6 , Cornelia Duscheck  7 , Ilse Muchitsch  8 , Christine Marosi  7 , Michael Schumacher  9 , Sabine Zöchbauer-Müller  7 , Raj K Manchanda  10 , Andrea Schrott  11 , Otto Burghuber  12
Affiliations
Randomized Controlled Trial

Homeopathic Treatment as an Add-On Therapy May Improve Quality of Life and Prolong Survival in Patients with Non-Small Cell Lung Cancer: A Prospective, Randomized, Placebo-Controlled, Double-Blind, Three-Arm, Multicenter Study

Michael Frass et al. Oncologist. 2020 Dec.

Erratum in

Expression of concern in

Abstract

Lessons learned: Conventional medicine and homeopathy work well together. Quality of life improves with additive homeopathy in patients with non-small cell lung cancer (NSCLC). Survival improves with additive homeopathy in patients with NSCLC.

Background: Patients with advanced non-small cell lung cancer (NSCLC) have limited treatment options. Alongside conventional anticancer treatment, additive homeopathy might help to alleviate side effects of conventional therapy. The aim of the present study was to investigate whether additive homeopathy might influence quality of life (QoL) and survival in patients with NSCLC.

Methods: In this prospective, randomized, placebo-controlled, double-blind, three-arm, multicenter, phase III study, we evaluated the possible effects of additive homeopathic treatment compared with placebo in patients with stage IV NSCLC, with respect to QoL in the two randomized groups and survival time in all three groups. Treated patients visited the outpatients' centers every 9 weeks: 150 patients with stage IV NSCLC were included in the study; 98 received either individualized homeopathic remedies (n = 51) or placebo (n = 47) in a double-blinded fashion; and 52 control patients without any homeopathic treatment were observed for survival only. The constituents of the different homeopathic remedies were mainly of plant, mineral, or animal origin. The remedies were manufactured by stepwise dilution and succussion, thereby preparing stable Good Manufacturing Practice grade formulations.

Results: QoL as well as functional and symptom scales showed significant improvement in the homeopathy group when compared with placebo after 9 and 18 weeks of homeopathic treatment (p < .001). Median survival time was significantly longer in the homeopathy group (435 days) versus placebo (257 days; p = .010) as well as versus control (228 days; p < .001). Survival rate in the homeopathy group differed significantly from placebo (p = .020) and from control (p < .001).

Conclusion: QoL improved significantly in the homeopathy group compared with placebo. In addition, survival was significantly longer in the homeopathy group versus placebo and control. A higher QoL might have contributed to the prolonged survival. The study suggests that homeopathy positively influences not only QoL but also survival. Further studies including other tumor entities are warranted.

Trial registration: ClinicalTrials.gov NCT01509612.

Keywords: Additive homeopathy; Adult oncology; Complementary and alternative medicine; Global health status; Lung cancer; Survival.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Kaplan‐Meier estimates of overall survival time in the three groups. Crosses indicate time points of censoring (i.e., no patients died after this time point in this study group). Bold italicized values are statistically significant.
Figure 2
Figure 2
Study protocol.Abbreviations: BL, baseline; verum, homeopathy; wks, weeks.
Figure 3
Figure 3
CONSORT diagram.
See this image and copyright information in PMC

References

    1. Cancer facts and statistics. American Cancer Society Web site. 2016. http://www.cancer.org/research/cancerfactsstatistics/index. Accessed February 22, 2017.
    1. Jemal A, Siegel R, Xu J et al. Cancer statistics. CA Cancer J Clin 2010;60:277–300. - PubMed
    1. Molina JR, Yang P, Cassivi SD et al. Non‐small cell lung cancer: Epidemiology risk factors, treatment, and survivorship. Mayo Clin Proc 2008;83:584–594. - PMC - PubMed
    1. Hirsch FR, Scagliotti GV, Mulshine JL et al. Lung cancer: Current therapies and new targeted treatments. Lancet 2017;389:299–311. - PubMed
    1. Ettinger DS, Wood DE, Aisner DL et al. Non‐small cell lung cancer, version 2017, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw 2017;15:504–535. - PubMed

Publication types

Associated data

LinkOut - more resources